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Men treated for localized prostate cancer by radiotherapy have often a remaining
life span of 10 yr or more. Therefore, the risk for secondary malignancies should be
taken into account. Plans for ten patients were evaluated which had been per-
formed on an Oncentra® treatment planning system for a treatment with an Elekta
Synergy™ linac with Agility™ head. The investigated techniques involved IMRT and
VMTA with and without flattening filter. Different dose response models were
applied for secondary carcinoma and sarcoma risk in the treated region and also in
the periphery. As organs at risk we regarded for carcinoma risk urinary bladder, rec-
tum, colon, esophagus, thyroid, and for sarcoma risk bone and soft tissue. The excess
absolute risk (EAR) was found very similar in the treated region for both techniques
(IMRT and VMAT) and also for both with and without flattening filter. The secondary
sarcoma risk resulted about one magnitude smaller than the secondary carcinoma risk.
The EAR to the peripheral organs was statistically significant reduced by application
of the flattening filter free mode concerning the flattening filter as main source of
scattered dose. Application of flattening filter free mode can thus support to reduce
second malignancy risk for patients with localized prostate cancer.
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1 | INTRODUCTION
Prostate cancer is the most frequently diagnosed cancer among men
in developed countries.1 Radiotherapy is a standard treatment
modality with curative intent for localized prostate cancer. Although
prostate cancer is a disease of elderly men, these patients have a
remaining life span of 10 yr or more and therefore the risk for sec-
ondary malignancies should be taken into account. Radiotherapy
compared to surgery may increase the risk for secondary cancer over
time,2–5 but there are also ambiguous results.5–7
Modern linear accelerators (linacs) promise shorter treatment
times using the flattening filter free (FFF) mode. The flattening filter
has been identified as the main source of scattered dose from the
treatment head.8,9 This dose might be responsible for additional sec-
ondary malignancy risk (SMR). Model calculations are regarded as a
first essential step to evaluate this risk as long as clinical observa-
tions are not available.10 Only a few investigations using model cal-
culations have been published about the impact of the FFF mode on
SMR. Besides works about patients with breast cancer,11 ependy-
moma,12 and pituitary adenoma13 there is only one paper evaluating
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the SMR for patients with prostate cancer treated with linacs with
and without flattening filter14 which confined to only three patients
at cost of statistical significance. Additionally, they used another
therapy planning system (TPS) which can affect the out-of-field
dose.15
Minimizing the SMR can be one criterion in the decision for a
specific technique apart from the plan quality. Therefore we com-
pared the excess absolute risk (EAR) for secondary malignancies for
the application of different fluence modulating treatment techniques,
intensity modulated radiation therapy (IMRT) and volumetric modu-
lated arc therapy (VMAT) with and without flattening filter.
2 | MATERIALS AND METHODS
2.A | Patients and regions of interest
Ten consecutive patients with histologically proven localized prostate
cancer were included in this planning study. At the start of radio-
therapy the patients had a mean age of 71 yr and all have given
their written informed consent for participation in the planning
study. The delineation of the regions of interest (ROI) in the TPS fol-
lowed the description of Bos et al.16: The clinical target volume
(CTV) was derived from the gross tumor volume (GTV) (prostate
gland and seminal vesicals) by adding a 5 mm three-dimensional mar-
gin excluding the rectal volume. Similarly, for the planning target vol-
ume (PTV) a margin of 10 mm was added to the GTV including parts
of the rectum. The following organs at risk (OAR) were delineated:
the rectal volume according to Guckenberger et al.,17 the urinary
bladder, and the femoral heads. The bone structures were contoured
automatically by standard bone window settings and corrected man-
ually where it was appropriate. Soft tissue was delineated by sub-
tracting bone and PTV from the outline contour.
2.B | Linear accelerator
For the measurements and for the modeling in the TPS a linear
accelerator type Elekta Synergy™ with Agility™ head (Elekta AB,
Stockholm, Sweden) was applied. The head operates 80 interdigitat-
ing leaf pairs with a projected width of 5 mm at isocenter. It has
been shown that the beam quality in flattened beam (FB) mode and
FFF mode of 6 MV photons is very similar for energy matched
Elekta machines18 what could be confirmed for the applied equip-
ment.19 The maximum dose rates are 500 monitor units (MU) per
minute for FB and 1700 MU per minute for FFF. The applied desk-
top software was Integrity R 3.2 and the record and verify system
was Mosaiq 2.50.
2.C | Treatment planning system
The TPS on which the optimizations were performed was Oncentra®
External Beam v4.5 (Nucletron®, an Elekta AB) using the CC algo-
rithm. Some publications have demonstrated the applicability of this
system for treatments of prostate cancer and other entities with
IMRT and VMAT and also for FB and FFF.12,20–28 Limitations of the
linear accelerator were considered setting the maximum of the vari-
able gantry speed to a value of 6 degree per second and the mini-
mum of the variable dose rate to a value of 20 MU per minute.
2.D | Planning
The planning was set as simultaneous integrated boost in 33 fractions,
aiming for 71.0 Gy minimum dose and 74.2 Gy maximum dose to the
CTV which was used as boost volume. A minimum dose of 59.4 Gy
was targeted for the PTV. For both modes FB and FFF, as well as both
techniques IMRT and VMAT we applied the same set of dose volume
objectives. The isocenter was localized to the center of the CTV.
The IMRT planning was performed to the study of Treutwein
et al.26 with seven equispaced beams at gantry angles of 0°, 51°,
103°, 154°, 206°, 257°, and 309° and a collimator angle of 0°. The
VMAT planning was optimized according to Treutwein et al.27 in a
single arc gantry rotation from 182° to 178° and a collimator angle
of 45°. Further planning details and investigations about the plan
quality have been described in an earlier work.28
The dose grid spacing was set to 0.25 cm and the dose deposi-
tion was calculated to medium.
2.E | Dose measurements
The measured dose to peripheral points was considered for the cal-
culation of secondary malignancy risk in the periphery. Although
these measurements have already been described in detail in the
already mentioned work about investigations concerning plan quality
28, this is repeated here in short to facilitate the understanding. Two
stacks of water equivalent material RW3 (PTW, Freiburg, Germany)
were combined with the upper part of an Alderson phantom (RSD
Inc., Long Beach, CA, USA) (Fig. 1). The caudal stack contained a 2D
array for plan verifications which is not part of the present investiga-
tion. In the cranial stack one ionization chamber was introduced at a
distance of 31 cm from the isocenter on the rotation axis of the
gantry. This point corresponds approximately to the position of the
transverse colon. To enable measurements in points corresponding
to the lower esophagus and the thyroid gland, two slices of the
Alderson phantom were replaced by PA material with bores for ion-
ization chambers. All chambers were of type 30016 and the very
similar 23332 (0.3 cm3 both) and connected to dosimeters of type
Unidos (all of PTW Freiburg, Germany). These peripheral dose values
will be labeled as PDcolon, PDesoph, and PDthyr.
2.F | Secondary malignancy risk
For the calculations of the secondary malignancy risk we used the
models of Schneider et al.29 These models are based on a combina-
tion of the investigations of Preston et al.30 about the Japanese A-
bomb survivors and of Dores et al.31 about secondary cancer of
Hodgkin’s patients after radiotherapy. We calculated the risk as
excess absolute risk (EAR). It describes the absolute difference of
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the number of malignancies between a treated group and an
untreated control group. It is expressed per 10.000 persons per year.
The EAR can be factorized in functions of the sex s, the age at expo-
sure e, the attained age a, and of the dose d.
EAR d,s,e,að Þ¼ μ s,e,að Þ f dð Þ (1)
Preston et al. showed that for low dose regions up to a total
dose D of about 2 Gy the linear dose response model is valid:
EARorg ¼ βEARDμ e,að Þ (2)
This linear dependence has also been assumed in a recent publi-
cation about 3D conformal radiation therapy of patients with pros-
tate cancer.32 Preston gives values for different organs for the slope
βEAR which refer to the Japanese population. In some cases gender
specific values are given. According Schneider et al. these Japanese
values were corrected for western population (United Kingdom, UK)
for selected organs29 (Table 1).
The EAR for different organs of volume VT in the treated region
was calculated with dose–volume data from the TPS by application





V Dið ÞβEARRED Dið Þμ e,að Þ (3)
Di is the dose in voxel i with volume V.βEAR is the initial slope
and the risk equivalent dose RED the dose dependent part. Factor µ
is used to calculate the risk for different ages:





We used an age at radiotherapy of e = 60 yr and an attained
age of a = 80 yr as proposed by Murray et al.14 The modifying
parameters γe and γa for age correction have been taken from Pre-
ston et al.30 The values for these parameters and others which are
explained hereafter are given in Table 2.
Schneider developed different models for carcinoma induction to
determine the RED:
• The mechanistic model which considers cell killing and fractiona-
tion effects
• The bell-shaped dose response model which neglects any repop-
ulation or repair effect
• The plateau model with full repopulation or repair.
The mechanistic model is the most complex and considers frac-
tionated treatment schedules with single fraction dose d up to a
total dose D:
RED Dð Þ¼ e
α0D
α0R
12RþR2eα0D 1Rð Þ2e α0R1RD
 
(5)
The parameter α’ has been derived from the linear-quadratic
model:
α0 ¼αþβd (6)
Schneider et al.29 demonstrated that the model is robust in vari-
ations of α/β. Therefore, they assumed α/β = 3 Gy for all tissues. R
is the repopulation and repair parameter. It equals 1 for full repop-
ulation or repair and 0 for no repair. In the limit of R to 0 the for-
mula can be simplified to the linear-exponential or bell-shaped
model:
RED Dð Þ¼Deα0D (7)
The plateau model is achieved in the limit of R to 1:
RED Dð Þ¼ 1eα0D
 
=α0 (8)
All three models were included in our investigation, as there is
still little knowledge about the accurate shape of dose–response
F I G . 1 . Setup of the phantom with
inserted ionisation chambers in three
positions.27
TAB L E 1 Correction of the linear slope in the linear EAR model for
western population.
Organ at risk βEAR (Japan) Correction factor βEAR (UK)
Thyroid gland 0.5 0.35 0.2
Colon 13 0.92 12
Urinary bladder 3.8 1.2 4.6
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relationships for radiation induced cancer.29 Additionally the model
for secondary sarcoma induction of bone and soft tissue was
applied. The formula is quite similar to the mechanistic model for
carcinoma induction, but contains an additional term:
RED Dð Þ¼ e
α0D
α0R
12RþR2eα0D 1Rð Þ2e α0R1RDα0RD
 
(9)
Schneider et al.29 derived parameters for different repair and
repopulation: Low repopulation (R = 0.1), intermediate repopulation
(R = 0.5), and full recovery (R = 1.0).
2.G | Statistics
We assumed as null hypothesis that the mean values are equal in
both treatment modes FB and FFF.
The type I error should be smaller than 5% (α = 0.05). The Wil-
coxon signed-rank test for paired samples was selected as statistical
test as the different plans were optimized on the identical sets of
patient images. To control the maximum experimentwise error rate
for multiple testing we applied the Bonferrroni–Holm correction.33
This correction considers the number n of evaluated variables or
more specifically the corresponding null hypothesis. The p values for
all n hypothesis are sorted in ascending order. Each hypothesis nm






The higher the number n of statistically evaluated variables (null
hypothesis), the smaller becomes p∗1.and hence the chance decreases
to find any p value smaller than this one. Therefore, two sums of
variables only were considered in this process. However, they
include all investigated EARs: The sum of all calculated EAR from the
dose volume histograms EARplansum and the sum of the EAR calculated
from the PD measurements EARPDsum.
3 | RESULTS
The EAR for secondary cancer of the urinary bladder and the
rectum for the selected age range depending on the risk model
is demonstrated in Figs. 2 and 3. Only slight differences
can be seen between IMRT and VMAT and also between FB
and FFF.
Box plots representing the EAR for secondary sarcoma risk of
bone and soft tissue are shown in Figs. 4 and 5. Both figures show
that the EAR is highest when the repopulation parameter R equals 1,
that means full repopulation. It decreases when the repopulation is
less complete. The risk for secondary sarcoma is about one order
smaller than for secondary cancer.
As described in the previous paragraph about statistics only
the sum of all EARs in the treated region was statistically evalu-
ated. For each of the secondary carcinoma models one sum was
calculated. For the sake of simplicity the sum for secondary sar-
coma was included for the intermediate repopulation R = 0.5
only. For the comparison of FB vs FFF no significance was found
for the VMAT plans with p values between 0.13 and 0.28; for
IMRT the difference between FB and FFF was found statistically
significant for the plateau model only (P = 0.005); with p values
of 0.08 (mechanistic model) and 0.61 (linear-quadratic model) the
EARplansum was found equivalent for FB and FFF in the other models.
Regarding the EARplansum mean value and standard deviation for the
plateau model numerically shows that the statistically significant
difference is without clinical importance (FB: 9.8  0.7; FFF:
9.7  0.7).
The EAR for the peripheral points was calculated using the linear
model and the dose values from Table 3. The risk was very low com-
pared to the secondary cancer risk in the treated region. Due to the
high linearity factor βEAR of the colon, this EAR has the major contri-
bution as shown in Fig. 6.
TAB L E 2 Initial slope βEAR, α according the linear-quadratic model and modifying parameters for the age correction.
29,30 The values below the







model (R = 0)
Plateau
model (R = 1) γe γa
α R α α
Urinary bladder 4.6a 0.219 0.06 0.213 0.633 −0.024 2.38
Rectum 0.73 0.033 0.56 0.031 0.065 −0.056 6.9
Thyroid 0.2a – – – – −0.046 0.6
Esophagus 3.2 – – – – – –
Colon 12a 0.001 0.99 0.001 0.001 −0.056 6.9
Soft tissue 0.60 0.060 0.5 −0.013 −0.56
3.30 0.040 0.1
0.35 0.093 1
Bone 0.20 0.067 0.5 −0.013 −0.56
1.7 0.019 0.1
0.10 0.010 1
aGender specific values, valid for men only.
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Again the sum EARPDsum was investigated statistically. For the FFF
plans it was found significantly lower than for the FB plans (P = 0.005)
at both techniques IMRT and VMAT. For IMRT the EARPDsum was
reduced by 12%, for VMAT by 20%. Using VMAT reduced the risk
compared to IMRT for 17% (FB) respectively 24% (FFF).
4 | DISCUSSION
Schneider pointed out that even the combination of the two
data sets of atomic bomb survivors and morbus Hodgkin patients
involves uncertainties and problems.29 Additionally, differences
F I G . 2 . EAR for secondary bladder
carcinoma including all plans: The boxes
indicate the inner quartiles, the whiskers
the outer quartiles; the boxes for the
plateau model are horizontal lines only.
Outliers and extreme values are indicated
by circles and asterisks.
F I G . 3 . EAR for secondary rectum
carcinoma including all plans: The boxes
indicate the inner quartiles, the whiskers
the outer quartiles. Outliers are indicated
by circles.
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in the three dose response models reveal a further range of pos-
sible values. Other procedures to calculate the second cancer risk
from dose volume data would probably again end in different
results as, for example, presented by Dasu et al. using cell
survival in application of the linear-quadratic model.34,35 There-
fore, our presented results must be regarded as a draft illustrat-
ing magnitude and relations of second cancer risk. In a
narrow sense they are only valid for the described material and
methods.
4.A | Secondary malignancy risk in the treated
volume
Schneider published for many investigated organs plots of the EAR
in dependence of the dose.29 For the urinary bladder the plateau
model is high above the other two models in the high dose region.
Although these plots end at a maximum dose of 40 Gy, it seems rea-
sonable that the results of the present study are similar, as the mod-
els are based on them.
F I G . 4 . EAR for secondary bone sarcoma
including all plans: The boxes indicate the
inner quartiles, the whiskers the outer
quartiles. Outliers are indicated by circles.
R is the parameter for repair and
repopulation and is represented by
different colors.
F I G . 5 . EAR for secondary soft-tissue
sarcoma including all plans: The boxes
indicate the inner quartiles, the whiskers
the outer quartiles. Outliers are indicated
by circles. R is the parameter for repair
and repopulation and is represented by
different colors.
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In another work Schneider stated a slight increase in the sec-
ondary malignancy risk in the comparison of IMRT and 3D conformal
technique in the treatment of prostate cancer,36 applying the bell-
shaped dose response model and the plateau model. This is in accor-
dance with the results presented by Murray et al. in a review37:
They demonstrated either none or slight increase only of secondary
cancer after radiation for prostate cancer. However, the majority of
the investigated 47 publications was at the basis of older techniques
without intensity modulation. We calculated a maximum value EAR
of about 5 per 10.000 men per year for both secondary urinary blad-
der and rectum carcinoma. This small number explains that differ-
ences are hardly detectable in clinical studies. Our results are of the
same magnitude as Murray’s, calculated on three sample plans14 for
patients with early prostate cancer.
Alvarez Moret et al. used the same dose response models in
their investigation about SMR for the treatment of ependymoma.
They stated that the difference between FB and FFF was statistically
not significant for the application of IMRT, whereas for VMAT FFF
the risk was significantly lower (2–3%) than for FB.12 Dobler et al.
applied the models to plans for right-sided breast cancer11 with and
without flattening filter. They also described a dependency on the
technique: for tangential arc VMAT the EAR at the contralateral
breast and lung was significantly reduced with FFF, no differences
were observed for VMAT, and for IMRT the EAR for the contralat-
eral lung even increased with FFF. These examples illustrate that dif-
ferent localizations and techniques must be investigated separately,
as such treatments depend on the patient, tumor location, and plan-
ning strategy.15
Brenner et al. evaluated second malignancies in patients with
prostate cancer after radiotherapy.2 They compared them to a con-
trol group who underwent surgery only in a database analysis. The
SMR was found significantly increased after radiotherapy. The docu-
mented risk increased to 1 radiation associated second malignancy in
70 patients who survived more than 10 yr. However, a detailed
comparison is not possible due to different tumor staging, age, inves-
tigated time period, and treatment technique. Davis et al. also stated
an increased risk for secondary rectum cancer after radiotherapy for
prostate cancer but did not confirm it for urinary bladder5 whereas
it was conversely stated by Neugut et al.7 Hegemann et al. doubt
that increased rates of second cancer are caused by radiotherapy
but assume lifestyle habits and comorbidities.6
The EAR for secondary sarcoma was found one magnitude smal-
ler than for secondary cancer. This result is in accordance to the
results of Preston et al. about the atomic bomb survivors.30
Although Schneider et al. concluded from data of radiotherapy
patients that the risk might be of similar magnitude than carcinoma
induction,29 this could not be confirmed for our given conditions.
Also Brenner et al. documented an increased secondary sarcoma risk
after radiotherapy which was smaller than the secondary carcinoma
risk.
Cahan et al. reported in an early investigation that secondary
bone sarcoma has rarely been observed after radiotherapy.38 Two
TAB L E 3 Peripheral dose in 3 points as shown in Fig. 1 for one
fraction.28
Point IMRT FB IMRT FFF VMAT FB VMAT FFF
PDcolon in mGy 3.6  0.4 3.0  0.3 3.4  0.4 2.5  0.4
PDesoph in mGy 1.5  0.1 1.3  0.1 1.1  0.1 0.7  0.1
PDthyr in mGy 1.3  0.1 1.1  0.2 1.2  0.1 0.6  0.1
F I G . 6 . EAR in the periphery calculated
from single point measurements. The
boxes indicate the inner quartiles, the
whiskers the outer quartiles. The three
groups represent from left to right: colon,
esophagus, and thyroid.
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recent studies about bone and soft tissue sarcoma after radiotherapy
of breast cancer reported an increased risk after radiotherapy.39,40
However, this would not override the benefit of radiotherapy. Virta-
nen et al. concluded that further investigation is necessary to resolve
the dose response of the previous ionizing radiation.41
4.B | Secondary malignancy risk in the periphery
For both techniques, IMRT and VMAT, the PD was smaller without
than with flattening filter. As it has been mentioned in the introduc-
tion, the flattening filter has been described as a main source of
scattered photons. However, the PD depends on many factors, as
distance from the primary beam, the design of the treatment head
including magnets and shielding material, and the treatment site.8,9
The PD reduction in FFF mode was found common for different
tumor localizations, linear accelerators, techniques, and
TPS.9,11,12,14,42 It has been found the only general advantage of FFF
in various normofractionated treatments.43
Similarly to Refs. [14,42] we measured that the mean PD
decreased with increasing distance from the field. However, this was
not valid in every single case when comparing the dose to the thy-
roid and the esophagus point in individual plans. Different collimator
configuration, head transmission dose, and scatter in the patient are
supposed to be responsible.
VMAT compared to IMRT results in a lower PD. This has also
been reported in some of the former mentioned publica-
tions.12,22,28,42 It seems contradictory to the higher number of MU
needed for VMAT in some of these reports — including our prostate
cases. Obviously the respective collimator configuration plays an
important role.
To our knowledge only in one study of Murray et al the SMR
was calculated from the PD, applying the linear model as well.14 Our
results were of the same magnitude regarding the esophagus and
the thyroid. With FFF the risk was statistically significant reduced.
As the SMR in the treated region is about one magnitude higher, the
risk from the PD plays minor role in the decision process for a par-
ticular technique or mode.
5 | CONCLUSIONS
The secondary malignancy risk in the radiotherapy treatment of
patients with localized prostate cancer is very similar for both tech-
niques (IMRT and VMAT) and both modes (FB and FFF) in the trea-
ted region. In peripheral regions it is statistically significant reduced
for FFF on a low level. This can support the decision for a particular
technique using FFF.
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